-
公开(公告)号：US20190315754A1
公开(公告)日：2019-10-17
申请号：US16391882
申请日：2019-04-23
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Wanjun Zheng , Xiaojie Zhu , Hong Du , Maarten Postema , Yimin Jiang , Jing Li , Robert Yu , Hyeong-wook Choi , Jaemoon Lee , Frank Fang , Daniel Custar
IPC: C07D487/04 , C07D519/00 , A61P35/00
Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
-
公开(公告)号：US20150182496A1
公开(公告)日：2015-07-02
申请号：US14595746
申请日：2015-01-13
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Sergei Agoulnik , Bruce Decosta , Hong Du , Yimin Jiang , Xiang-Yi Li , Kenichi Nomoto , John (Yuan) Wang , Huiming Zhang
IPC: A61K31/365 , A61K31/496 , A61K45/06 , A61K31/4025 , A61K31/422 , A61K31/665 , A61K31/4178 , A61K31/5377
CPC classification number: A61K31/365 , A61K31/4025 , A61K31/4178 , A61K31/422 , A61K31/4523 , A61K31/496 , A61K31/5377 , A61K31/665 , A61K45/06
Abstract: The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R1-R3 are as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.
Abstract translation: 本发明提供了用于治疗特定癌症的化合物，药物组合物和方法。 这样的组合物通常可以包含式（I）的化合物：其中R 1 -R 3如本文所定义，或其药学上可接受的盐或酯; 和药学上可接受的载体。
-
公开(公告)号：US11160783B2
公开(公告)日：2021-11-02
申请号：US15960259
申请日：2018-04-23
Applicant: Eisai R&D Management Co., LTD.
Inventor： Sergei Agoulnik , Bruce Decosta , Hong Du , Yimin Jiang , Xiang-Yi Li , Kenichi Nomoto , John (Yuan) Wang , Huiming Zhang
IPC: A61K31/365 , A61P35/00 , A61K31/4025 , A61K31/4178 , A61K31/422 , A61K31/4523 , A61K31/496 , A61K31/5377 , A61K31/665 , A61K45/06
Abstract: The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R1-R3 are as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.
-
公开(公告)号：US10316040B2
公开(公告)日：2019-06-11
申请号：US15768668
申请日：2016-10-14
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Wanjun Zheng , Xiaojie Zhu , Hong Du , Maarten Postema , Yimin Jiang , Jing Li , Robert Yu , Hyeong-wook Choi , Jaemoon Lee , Frank Fang , Daniel Custar
IPC: C07D487/04 , C07D519/00 , A61P35/00
Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
-
Patent Agency Ranking
公开(公告)号：US11434246B2
公开(公告)日：2022-09-06
申请号：US17141557
申请日：2021-01-05
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Wanjun Zheng , Xiaojie Zhu , Hong Du , Maarten Postema , Yimin Jiang , Jing Li , Robert Yu , Hyeong-Wook Choi , Jaemoon Lee , Francis G. Fang , Daniel Custar
IPC: C07D487/04 , C07D519/00 , A61P35/00
Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
-
公开(公告)号：US10941148B2
公开(公告)日：2021-03-09
申请号：US16391882
申请日：2019-04-23
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Wanjun Zheng , Xiaojie Zhu , Hong Du , Maarten Postema , Yimin Jiang , Jing Li , Robert Yu , Hyeong-wook Choi , Jaemoon Lee , Frank Fang , Daniel Custar
IPC: C07D487/04 , C07D519/00 , A61P35/00
Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
-
公开(公告)号：US20180353468A1
公开(公告)日：2018-12-13
申请号：US15960259
申请日：2018-04-23
Applicant: Eisai R&D Management Co., LTD.
Inventor： Sergei Agoulnik , Bruce Decosta , Hong Du , Yimin Jiang , Xiang-Yi Li , Kenichi Nomoto , John (Yuan) Wang , Huiming Zhang
IPC: A61K31/365 , A61K45/06 , A61K31/4025 , A61K31/4178 , A61K31/422 , A61K31/496 , A61K31/5377 , A61K31/665 , A61K31/4523
CPC classification number: A61K31/365 , A61K31/4025 , A61K31/4178 , A61K31/422 , A61K31/4523 , A61K31/496 , A61K31/5377 , A61K31/665 , A61K45/06
Abstract: The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R1-R3 are as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.
-
公开(公告)号：US20180305362A1
公开(公告)日：2018-10-25
申请号：US15768668
申请日：2016-10-14
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Wanjun Zheng , Xiaojie Zhu , Hong Du , Maarten Postema , Yimin Jiang , Jing Li , Robert Yu , Hyeong-wook Choi , Jaemoon Lee , Frank Fang , Daniel Custar
IPC: C07D487/04 , C07D519/00 , A61P35/00
CPC classification number: C07D487/04 , A61P35/00 , C07D519/00
Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
-
公开(公告)号：US08937056B2
公开(公告)日：2015-01-20
申请号：US13794635
申请日：2013-03-11
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Sergei Agoulnik , Bruce Decosta , Hong Du , Yimin Jiang , Xiang-Yi Li , Kenichi Nomoto , John (Yuan) Wang , Huiming Zhang
IPC: A01N57/00 , A61K31/665 , A01N43/02 , A61K31/335 , A01N43/76 , A61K31/42 , A61K31/415 , A61K31/497 , A61K31/535 , A61K31/4178 , A61K31/365 , A61K31/422 , A61K31/5377 , A61K45/06 , A61K31/496 , A61K31/4025 , A61K31/4523
CPC classification number: A61K31/365 , A61K31/4025 , A61K31/4178 , A61K31/422 , A61K31/4523 , A61K31/496 , A61K31/5377 , A61K31/665 , A61K45/06
Abstract: The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R1-R3 are as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.
Abstract translation: 本发明提供了用于治疗特定癌症的化合物，药物组合物和方法。 这样的组合物通常可以包含式（I）的化合物：其中R 1 -R 3如本文所定义，或其药学上可接受的盐或酯; 和药学上可接受的载体。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.03 seconds)
